ClinicalTrials.gg
RecruitingNCT07728513Updated Sep 17, 2026

Improving AI-Assisted Medical Diagnosis and Triage by the General Public

An interventional study of new GPT-4o Interface and Control in AI-Assisted Diagnosis and Large Language Models, sponsored by Lahore University of Management Sciences. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-17.

Primary conditionnone(registry's first term: Disease)No conditionIs this wrong?Disease describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Lahore University of Management Sciences · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a randomized controlled trial (RCT) investigating whether access to a new LLM interface can improve medical triage and diagnostic accuracy for laypeople compared to access to a standard LLM interface. It addresses previous findings where laypeople using standard LLMs performed worse than those using conventional methods (e.g., web search) due to incomplete symptom sharing and poor interpretation of AI advice. To address this, the research tests a structured LLM system that proactively asks clinical history questions before providing a standardized, easy-to-read diagnostic output.

Read the detailed description

As large language models (LLMs) become widely accessible, a growing share of the public already turns to AI-powered chatbots for health-related information: surveys suggest that one in six American adults consults AI chatbots for health queries at least once a month. At the same time, diagnostic errors and misplaced triage decisions represent a persistent source of preventable patient harm globally [4]. This has prompted considerable interest in whether LLMs can serve as a reliable "front door" to the healthcare system for patients who lack immediate access to a clinician.

However, incidents involving misguided medical suggestions from LLMs to the general public such as fatal overdose and erroneous diagnosis leading to life-threatening treatment delay have been reported. A recent controlled study shows LLMs perform significantly worse for medical assistance in real-world settings compared to their performance on controlled benchmarks. Bean et al. [1] conducted a large preregistered study with 1,298 UK participants in which laypeople were assigned to receive assistance from one of three popular LLMs (GPT-4o, Llama 3, or Command R+) or to use a source of their choice when assessing ten standardized medical scenarios. Although the LLMs alone correctly identified relevant conditions in up to 94.9% of cases, participants using those same LLMs did so in fewer than 34.5% of cases, significantly worse than the group using their typical home resources (∼60%). Similarly, triage accuracy showed no signifcant difference between LLM users and controls, with an overall correct response rate of 43.0% across all groups. This poor performance can be linked to two main failure modes: users providing incomplete symptom information to the AI, and users failing to correctly interpret or act upon the LLM's output.

To address these failure modes, the study tests a new GPT-4o interface wrapped with a fixed system prompt. Rather than passively responding to whatever the user volunteers, the AI is instructed to ask clarifying questions to gather a proper clinical history before offering any medical suggestions. Once the model judges that enough information is gathered, it provides a structured, easy-to-read response detailing possible conditions, their likelihoods, and a clear triage recommendation.

The trial is structured as a two-arm, single-blind RCT. Both arms retain access to whatever assistance methods participants would normally use at home (e.g., web search), and both arms additionally get a GPT-4o-based LLM interface. The difference lies in which interface: the treatment arm receives the new interface described above, while the control arm receives a standard, unmodified GPT-4o interface with no special prompting. Participants are restricted to using the provided LLM interface (GPT-4o) only, and not other LLMs. AI-overview in web searches will be disabled through an extension. The trial utilizes ten previously validated clinical vignettes covering various medical urgencies, ranging from self-care routines up to ambulance-level emergencies, with each participant randomly assigned two of the ten. To achieve sufficient statistical power (accounting for within-participant clustering across those two responses), the target sample size is calculated at 220 total participants, split evenly with 110 individuals per arm.

The participant pool is drawn from the enrolled students and administrative staff at the Lahore University of Management Sciences (LUMS) in Pakistan. To ensure the sample consists strictly of laypeople, anyone currently enrolled in or who has completed a medical, nursing, or allied health professional degree is explicitly excluded from participating.

The study is driven by two co-primary hypotheses: participants with access to the new LLM interface will identify relevant medical conditions at a higher rate than participants using the standard LLM interface, and they will correctly assess the urgency of the medical scenarios at a higher rate. Accuracy is measured by comparing participant responses to a physician-generated gold-standard list using fuzzy matching, then analyzed via mixed-effects logistic regression with participant-level covariates and a Bonferroni-corrected significance threshold. The study also tracks secondary outcomes - self-reported confidence and time spent per scenario - and several exploratory analyses, including an LLM-alone benchmark, moderation by LLM experience, internet usage patterns, digital literacy, and scenario-level variation in accuracy.

02

Conditions studied

  • AI-Assisted Diagnosis
  • Large Language Models

Browse trials for

Keywords

  • LLMs
  • Diagnosis
  • Triage
03

In context

Lead sponsor

Lahore University of Management Sciences is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Enrolled student or employed administrative staff at LUMS.
  • 18 years of age or older.
  • Able to read and understand English.

Exclusion criteria

Exclusion Criteria:

  • Individuals with any formal education or professional training in medicine, nursing, or any other healthcare profession.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Treatment Arm (new GPT-4o Interface)

    Participants can access any assistance methods they would typically employ (e.g., web search or health portals) in addition to a new LLM interface (based on GPT-4o) to complete medical scenarios. The new LLM interface uses a fixed system prompt that (a) instructs the model to ask targeted clarifying questions before providing any diagnostic or triage suggestions, and (b) requires all final responses to follow a structured template listing: possible conditions, approximate likelihood of each, and a recommended triage with brief reasoning.

    Device: new GPT-4o Interface

  • Placebo comparator
    Control

    Participants can use any assistance methods they would typically employ (e.g., web search or health portals) in addition to a standard LLM (GPT-4o) to complete medical scenarios. AI-overview in web searches will be disabled via an extension. They would not be allowed to access any LLMs other than the standard LLM interface.

    Other: Control

Interventions

  • Devicenew GPT-4o Interface

    Participants can access any assistance methods they would typically employ (e.g., web search or health portals) in addition to a new LLM (GPT-4o) interface to complete medical scenarios. The new LLM interface uses a fixed system prompt that (a) instructs the model to ask targeted clarifying questions before providing any diagnostic or triage suggestions, and (b) requires all final responses to follow a structured template listing: possible conditions, approximate likelihood of each, and a recommended triage with brief reasoning.

  • OtherControl

    Participants use any assistance methods they would typically employ at home (e.g., Google or health portals) in addition to a standard LLM (GPT-4o) to complete medical scenarios. AI-overview in web searches will be disabled via an extension. They would not be allowed to access any LLMs other than the standard LLM interface.

06

What researchers measure

Primary outcomes

  1. Urgency Assessment Accuracy

    The primary outcome will be the percentage of correct urgency assessments, ranging from 0 to 100%, where higher scores indicate better urgency assessment (or triage) performance. The rating which participants give for the urgency of each case, will be measured on a five-point scale: Self-care, Routine GP, Urgent Primary Care, Accident \& Emergency, and Ambulance. Responses will be compared against the gold-standard answers to produce an accuracy measure. The primary outcome will be compared at the case-level between the randomized groups.

    Time frame: Assessed at a single time point for each case, during the scheduled diagnostic evaluation session, which takes place between 0-5 days after participant enrollment.

  2. Condition Identification Accuracy

    The co-primary outcome is the Condition Identification Accuracy, which is the percentage of cases in which the condition was correctly identified, ranging from 0 to 100%., where higher scores indicate better medical condition identification performance. Participants name all medical conditions they considered relevant to their decision. A response is scored as correct for that scenario if at least one named condition matches the physician-generated gold-standard list of relevant conditions. The co-primary outcome will be compared at the case-level between the randomized groups.

    Time frame: Assessed at a single time point for each case, during the scheduled diagnostic evaluation session, which takes place between 0-5 days after participant enrollment.

Secondary outcomes

  1. Self-Reported Confidence

    Participants' self-reported confidence in their urgency assessments, measured using a scale ranging from 0 to 100.

    Time frame: Assessed at a single time point for each case, during the scheduled diagnostic evaluation session, which takes place between 0-5 days after participant enrollment.

  2. Time Spent

    The amount of time participants spend completing each medical scenario in milliseconds.

    Time frame: Assessed at a single time point for each case, during the scheduled diagnostic evaluation session, which takes place between 0-5 days after participant enrollment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07728513
Lead sponsor
Lahore University of Management Sciences
Responsible party
Ihsan Ayyub Qazi, PhD (Professor, Lahore University of Management Sciences) — Principal investigator
First posted
Jul 27, 2026
Start date
Jul 1, 2026
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Ihsan Ayyub Qazi, PhD
Contact
ihsan.qazi@lums.edu.pk
+923233333766
Ayesha Ali, PhD
Contact
ayeshaali@lums.edu.pk
04235608368
Ihsan Ayyub Qazi, PhD
study chair · Lahore University of Management Sciences (LUMS)
Ayesha Ali, PhD
principal investigator · Lahore University of Management Sciences (LUMS)
Zafar Ayyub Qazi, PhD
principal investigator · Lahore University of Management Sciences (LUMS)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion